|
rs7023329
|
|
|
0.810 |
GeneticVariation |
BEFREE |
One SNP in MTAP (methylthioadenosine phosphorylase) (rs7023329) that was previously associated with melanoma and nevi in multiple genome-wide association studies was associated with CRC, CA and OS by ASSET (P=0.007).
|
23361049 |
2013 |
|
rs17119461
|
|
|
0.810 |
GeneticVariation |
GWASDB |
A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.
|
21706340 |
2012 |
|
rs17119461
|
|
|
0.810 |
GeneticVariation |
GWASCAT |
A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.
|
21706340 |
2012 |
|
rs7023329
|
|
|
0.810 |
GeneticVariation |
GWASDB |
A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.
|
21706340 |
2012 |
|
rs1801516
|
|
|
0.810 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies three new melanoma susceptibility loci.
|
21983787 |
2011 |
|
rs1801516
|
|
|
0.810 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies three new melanoma susceptibility loci.
|
21983787 |
2011 |
|
rs7023329
|
|
|
0.810 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies three new melanoma susceptibility loci.
|
21983787 |
2011 |
|
rs7023329
|
|
|
0.810 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies three new melanoma susceptibility loci.
|
21983787 |
2011 |
|
rs7023329
|
|
A |
0.810 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies three loci associated with melanoma risk.
|
19578364 |
2009 |
|
rs7023329
|
|
A |
0.810 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies three loci associated with melanoma risk.
|
19578364 |
2009 |
|
rs910873
|
|
|
0.810 |
GeneticVariation |
BEFREE |
Our results do not support an association between CMM and any of the STX17 SNPs and provide no evidence for interactions between the melanoma risk SNP rs910873 on chromosome 20 and any of the STX17 SNPs.
|
19209086 |
2009 |
|
rs910873
|
|
T |
0.810 |
GeneticVariation |
GWASCAT |
Using pooling, we identified a new melanoma risk locus on chromosome 20 (rs910873 and rs1885120), with replication in two further samples (combined P < 1 x 10(-15)).
|
18488026 |
2008 |
|
rs910873
|
|
T |
0.810 |
GeneticVariation |
GWASDB |
Using pooling, we identified a new melanoma risk locus on chromosome 20 (rs910873 and rs1885120), with replication in two further samples (combined P < 1 x 10(-15)).
|
18488026 |
2008 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600R-mutant melanoma accounts for a significant number of cases even in single-institution practices.
|
31305324 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs1057519695
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The activating NRAS p.Q61R variant is a known "hotspot" variant, frequently identified in several types of human cancer, especially melanoma.
|
30542204 |
2019 |